Kennedy Institute of Ethics Journal 20 (2):161-179 (2010)

In the debates surrounding the ethical dimensions of interventions in the human genome, much attention is paid to determining whether—and if so, how—market access to these technologies ought to be managed in order to maximize social benefit. There are those who advocate a “laissez-faire” free-market approach to the development and use of genetic and genomic interventions. We are sympathetic to this view insofar as we understand the workings of the market stimulus effect. We use the term “market stimulus effect” to refer to the outcome of a set of mechanisms whereby early adoption of a new technology by wealthy consumers promotes the development of versions of this product that are cheaper to produce, or are simply ..
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1353/ken.0.0310
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy

Upload a copy of this paper     Check publisher's policy     Papers currently archived: 56,060
Through your library

References found in this work BETA

No references found.

Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles

Germ-Line Genetic Enhancement and Rawlsian Primary Goods.Fritz Allhoff - 2005 - Kennedy Institute of Ethics Journal 15 (1):39-56.
Germ-Line Enhancement of Humans and Nonhumans.J. Robert Loftis - 2005 - Kennedy Institute of Ethics Journal 15 (1):57-76.
Genetic Enhancement: Plan Now to Act Later.Maxwell J. Mehlman - 2005 - Kennedy Institute of Ethics Journal 15 (1):77-82.
The Ethics and Economics of Patenting the Human Genome.Edward B. Flowers - 1998 - Journal of Business Ethics 17 (15):1737-1745.


Added to PP index

Total views
49 ( #202,572 of 2,403,824 )

Recent downloads (6 months)
1 ( #550,507 of 2,403,824 )

How can I increase my downloads?


My notes